The Specialty Pharma Outfit That Refuses to Stop Winning

Meet India’s Most Boring Boring Story—Which Somehow Returned 35% in 3 Years

Ajanta Pharma is not trendy. No blockchain pivot. No AI angle. No celebrity endorsements. Just 50-year-old niche drug maker selling the same heart pills, eye drops, dermatology creams, and pain management drugs to hospitals, clinics, and distributors across 30+ countries. Its idea of innovation is launching 70 new products in a year and expanding its field force. Yawn.

Except—and this is the annoying part if you’re a competitor—this “boring” business has delivered 35% stock CAGR over three years, 34% ROCE, consistent double-digit revenue growth, and PAT margins locked at 19-20% for over a decade. Management doesn’t do earnings calls dressed as startup pitches. It doesn’t promise the moon. It just executes quarter after quarter, launches products in underserved therapeutic areas (cardiology, ophthalmology, dermatology, pain), and lets the numbers speak for themselves.

Q3 FY26 is the latest chapter in this no-drama success story. Highest-ever quarterly revenue, profit jump, and now the company is explicitly hunting for acquisitions with cash reserves of ₹1,000+ crore. The announcement came buried in the concall—not in a press release, not in a flash—because Ajanta values execution over headline generation.

The business operates across three geographies: India branded generics (31% of revenue, outpacing market), US generics (26% of revenue, growing at 52% YoY), and Asia-Africa branded generics (40%, with Africa on fire). Most pharma companies would split their focus. Ajanta is doubling down on all three simultaneously while prepping a GLP-1 (semaglutide) launch and signing emerging-market partnerships. It’s a masterclass in operational ambition with financial discipline.

Specialty Drugs for Conditions Nobody Talks About (But Everyone Has)

Ajanta operates three parallel business engines, each with its own profit logic. First: India Branded Generics—500+ products across niche therapeutic areas. Cardiology (36% of mix), ophthalmology (30%), dermatology (24%), pain management (10%). Take cardiology: instead of fighting in the commodity hypertension space, Ajanta owns sub-segments like ACE inhibitors where they rank #16 nationally but command much higher margins due to focused field execution. Same playbook in ophtho: Bimat (eye lash serum) is a category-creator with zero marketing spend. Dermatology saw 2x growth in Q3, rising two ranks. The field force is now 3,750 MRs (up 300 in 9M) and specifically trained for chronic therapy selling, not volume chasing.

Second: US Generics—their fastest-growing profit engine, doing ₹1,052 crore in 9M (26% of revenue, up 46% YoY). Ajanta files for complex-delivery generics (extended-release, delayed-release tablets) at the USFDA with 49 approved ANDAs (up from zero in FY16). They’ve positioned themselves as a “preferred partner” to US distributors by offering reliable supply and quality at scale. In Q3 alone, they launched 8 new products and saw seasonality benefits from a flu product. Management expects FY27 to remain double-digit but slower than FY26’s 46%.

Third: Asia-Africa Branded—₹679 crore in 9M (40% of revenue). Africa outperformed plan with 33% growth in Q3 (vs plan for mid-single digit). Asia had temporary softness (down 9% in Q3) due to logistics delays and market-traction issues, but management expects normalization from Q4. The company launched 13 new products in Asia in 9M and 7 in Africa. Both are positioned as emerging-market plays with 23-30 high-margin sub-segments per country.

Q3 FY26: The Numbers That Whisper (Not Shout)

Result type: Quarterly Results  |  Q3 FY26 EPS: ₹21.91  |  Annualised EPS (Q3×4): ₹87.64  |  Full-year FY26 EPS (9M): ₹59.79 (9M average quarterly)

What’s This Specialty Machine Actually Worth?